Our best in silico screening-derived inhibitor of the interaction between ERCC1 and XPF was active in an NER assay in melanoma cells (IC50 20 μM), but caused only a small (1.3-fold) reduction in the cisplatin IC50 [27]. This evidence concerns the gene ERCC1 and melanoma.